Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for ...

FibroGen ( ($FGEN) ) just unveiled an announcement. On August 18, 2025, FibroGen announced that it received regulatory approval from the China ...

FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong ...

Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Marke ...

FibroGen Inc (FGEN) reports significant cost reductions and a strengthened cash position, setting the stage for future growth ...

Analysts anticipate FibroGen to report an earnings per share (EPS) of $-0.30. Investors in FibroGen are eagerly awaiting the ...

Detailed price information for Fibrogen Inc CS (FGEN-Q) from The Globe and Mail including charting and trades.

Gain insights into FibroGen’s Q2 2025 earnings call, highlighting trial progress, regulatory updates, and increased cash runway.

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now esti ...

Detailed price information for Fibrogen Inc CS (FGEN-Q) from The Globe and Mail including charting and trades.

Investing.com -- FibroGen Inc (NASDAQ: FGEN) stock jumped 9.9% following positive feedback from the U.S. Food and Drug Administration supporting the advancement of roxadustat for treating anemia in ...

Find the latest FibroGen, Inc. (FGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.